IBOV 166,376.43 ▼ 0.69% COLCAP 2,452.46 — — IPC MEX 68,629.46 ▼ 0.12% MERVAL 2,848,945 — — USD/BRL5.91▼ 0.70% USD/MXN19.14▲ 0.30% USD/CLP 1,022 — 0.00% USD/COP3,483▲ 3.77% USD/PEN3.45▲ 0.19% USD/ARS1,580▲ 0.93% USD/UYU40.61▲ 3.16% USD/PYG6,212▲ 2.34% USD/BOB11.64▲ 2.55% USD/DOP59.52▼ 0.80% USD/CRC441.73▲ 2.68% USD/GTQ7.64▲ 3.22% USD/HNL26.89▲ 3.31% USD/NIO 36.62 — 0.00% USD/VES913.46▼ 0.45% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.59▲ 2.60% USD/TTD6.70▲ 2.00% EUR/BRL6.52▲ 1.12% BRENT 89.95 ▼ 2.21% WTI 83.41 ▲ 0.24% IRON ORE 161.91 — — COPPER 5.49 ▼ 2.49% GOLD 3,515 ▼ 4.62% SILVER 41.07 ▼ 7.33% SOY 1,221 ▲ 1.10% CORN 448.75 ▲ 2.22% WHEAT 592.00 ▲ 2.38% COFFEE 273.35 ▼ 3.08% SUGAR 17.07 ▼ 0.52% ORANGE JUICE 129.25 ▼ 2.49% COTTON 79.30 ▲ 4.41% COCOA 5,150 ▲ 1.72% BEEF 227.70 ▲ 2.18% CATTLE 335.43 ▼ 0.78% LITHIUM 51.98 ▼ 4.33% PETR4 42.67 ▼ 1.16% VALE3 58.48 ▼ 0.88% ITUB4 40.07 ▼ 0.30% BBDC4 13.83 ▼ 1.78% ABEV3 16.08 ▲ 0.06% BBAS3 14.30 ▲ 1.27% B3SA3 14.28 ▼ 0.14% WEGE3 51.13 ▼ 0.49% PRIO3 60.20 ▼ 2.70% SUZB3 55.32 ▼ 0.50% RENT3 28.86 ▼ 2.00% AZZA3 14.63 ▼ 7.29% CSAN3 3.08 ▼ 1.60% RAIZ4 15.00 ▼ 10.71% PCAR3 3.23 ▲ 8.03% GMAT3 4.18 ▲ 3.21% PSSA3 43.96 ▼ 1.57% CVCB3 0.72 ▼ 7.69% POSI3 3.37 ▲ 6.31% SLCE3 17.53 ▼ 1.96% NATU3 4.48 ▼ 6.28% BRKM5 2.60 ▼ 1.14% RANI3 8.01 ▼ 0.74% IBOV 166,376.43 ▼ 0.69% COLCAP 2,452.46 — — IPC MEX 68,629.46 ▼ 0.12% MERVAL 2,848,945 — — USD/BRL 5.91 ▼ 0.70% USD/MXN 19.14 ▲ 0.30% USD/CLP 1,022 — 0.00% USD/COP 3,483 ▲ 3.77% USD/PEN 3.45 ▲ 0.19% USD/ARS 1,580 ▲ 0.93% USD/UYU 40.61 ▲ 3.16% USD/PYG 6,212 ▲ 2.34% USD/BOB 11.64 ▲ 2.55% USD/DOP 59.52 ▼ 0.80% USD/CRC 441.73 ▲ 2.68% USD/GTQ 7.64 ▲ 3.22% USD/HNL 26.89 ▲ 3.31% USD/NIO 36.62 — 0.00% USD/VES 913.46 ▼ 0.45% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.59 ▲ 2.60% USD/TTD 6.70 ▲ 2.00% EUR/BRL 6.52 ▲ 1.12% BRENT 89.95 ▼ 2.21% WTI 83.41 ▲ 0.24% IRON ORE 161.91 — — COPPER 5.49 ▼ 2.49% GOLD 3,515 ▼ 4.62% SILVER 41.07 ▼ 7.33% SOY 1,221 ▲ 1.10% CORN 448.75 ▲ 2.22% WHEAT 592.00 ▲ 2.38% COFFEE 273.35 ▼ 3.08% SUGAR 17.07 ▼ 0.52% ORANGE JUICE 129.25 ▼ 2.49% COTTON 79.30 ▲ 4.41% COCOA 5,150 ▲ 1.72% BEEF 227.70 ▲ 2.18% CATTLE 335.43 ▼ 0.78% LITHIUM 51.98 ▼ 4.33% PETR4 42.67 ▼ 1.16% VALE3 58.48 ▼ 0.88% ITUB4 40.07 ▼ 0.30% BBDC4 13.83 ▼ 1.78% ABEV3 16.08 ▲ 0.06% BBAS3 14.30 ▲ 1.27% B3SA3 14.28 ▼ 0.14% WEGE3 51.13 ▼ 0.49% PRIO3 60.20 ▼ 2.70% SUZB3 55.32 ▼ 0.50% RENT3 28.86 ▼ 2.00% AZZA3 14.63 ▼ 7.29% CSAN3 3.08 ▼ 1.60% RAIZ4 15.00 ▼ 10.71% PCAR3 3.23 ▲ 8.03% GMAT3 4.18 ▲ 3.21% PSSA3 43.96 ▼ 1.57% CVCB3 0.72 ▼ 7.69% POSI3 3.37 ▲ 6.31% SLCE3 17.53 ▼ 1.96% NATU3 4.48 ▼ 6.28% BRKM5 2.60 ▼ 1.14% RANI3 8.01 ▼ 0.74%
since 2009
Sunday, November 22, 2026

Brazil Business & Economy

Profarma Q2 Revenue Jumps 32% to US$703 Million

Brazilian drug distributor Profarma delivered a strong second quarter: revenue jumped nearly a third to R$3.58 billion (US$703 million), profit rose, and the company said it hit record results while paying down debt.

By · · 4 min read
Medicines on the shelves of a Brazilian pharmacy
Grupo Profarma distributes medicines to pharmacies and hospitals across Brazil.

Brazil · Earnings

Brazilian drug distributor Profarma delivered a strong second quarter: revenue jumped nearly a third to R$3.58 billion (US$703 million), profit rose, and the company said it hit record results while paying down debt.

RT
Ask Rio Times
Latin American markets, currencies and companies.
Open the full Ask Rio Times →

Key Facts

Revenue. Net revenue reached R$3.58 billion (US$703 million) in the second quarter of 2026, up 32.4% year on year.

Profit. Adjusted net income was R$31.7 million (US$6.2 million), up from R$25.6 million a year earlier.

Record. The company reported record results, with growth in both business units.

Leverage. Net debt fell to 0.7 times EBITDA.

Brazil’s pharmaceutical market is the largest in Latin America, fueled by an aging population and expanded access to medicines through the public health system. Distributors like Profarma operate in a fiercely competitive space, where efficiency in logistics and inventory management separates winners from the rest.

The numbers

Grupo Profarma (B3: PFRM3), one of Brazil’s largest pharmaceutical distributors, reported net revenue of R$3.58 billion (about US$703 million) for the second quarter of 2026, a 32.4% increase on the same period last year. Adjusted net income came in at R$31.7 million (US$6.2 million), up from R$25.6 million a year earlier.

The company described the quarter as delivering record results, with growth across both of its business units and a reduction in leverage to 0.7 times EBITDA.

Such a sharp revenue uptick in a distributor reliant on high volume signals that both pharmacy chains and hospital clients stepped up orders. Steady demand for chronic-disease medications and seasonal illnesses likely made a contribution, though the company did not break out the exact drivers.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Brazil's lower house takes up Lula's fiscal bill”

Bringing net debt down to just 0.7 times EBITDA is a notable achievement for a capital-intensive wholesaler. This level of leverage gives Profarma room to fund working capital without straining its balance sheet, and it speaks to disciplined cash generation in the quarter.

Profit growth, while solid on an adjusted basis, also reflects the thin margin reality of drug distribution. For every R$100 in revenue, only a fraction trickles down to the bottom line, so top-line expansion of 32% must be managed with tight cost control to deliver meaningful earnings increases.

Two ways to read the profit

One number deserves a footnote. On an adjusted basis, net income rose to R$31.7 million, an increase of roughly a quarter.

On a reported basis, Profarma said profit climbed 53.6% — a larger jump that reflects one-off and accounting items stripped out of the adjusted figure. Both are the company’s own numbers; the adjusted measure is the cleaner gauge of underlying performance.

The reported figure captures the full bottom line, including all financial events during the quarter. For a true picture of operating health, however, market watchers tend to focus on the adjusted profit trend.

Differences between adjusted and reported profits often arise from one-time gains, tax adjustments, or asset revaluation effects. Investors typically use the adjusted number to gauge ongoing profitability, especially in capital-intensive sectors like distribution.

Why it matters

Pharmaceutical distribution is a high-volume, thin-margin business, so a 32% revenue jump paired with lower leverage is a meaningful signal of operating momentum for Profarma. As a middleman between drugmakers and Brazil’s pharmacies and hospitals, the company’s results also offer a read on demand across the country’s health system — and the record quarter suggests that demand, and Profarma’s share of it, kept expanding through mid-2026.

Brazil’s pharmacy and hospital sectors are highly fragmented, making an efficient distribution network a critical link in the supply chain. Profarma’s ability to deliver medicines on time and at scale helps determine its market share growth.

Growing demand for generic medicines and biologicals in Brazil’s public and private health systems is altering volume dynamics for distributors. Profarma’s record quarter points to its capacity to capture these new flows.

Reducing debt while expanding sales suggests the company is generating sufficient free cash flow, a positive sign in an industry that often ties up capital in inventories. Investors will be watching whether this operating rhythm can be sustained in the second half of the year.

Profarma’s shares on the B3 exchange may respond to the earnings beat, though market conditions and sector trends play a role. The results could attract attention from investors seeking exposure to Brazilian healthcare without taking on direct pharma risk.

Frequently Asked Questions

How did Profarma perform in Q2?
Net revenue rose 32.4% to R$3.58 billion (US$703 million), with adjusted net income of R$31.7 million.

What is Profarma?
Grupo Profarma (PFRM3) is a Brazilian pharmaceutical distributor supplying pharmacies and hospitals.

Did it reduce debt?
Yes — leverage fell to 0.7 times EBITDA, alongside record results in both business units.

Connected Coverage

Brazil’s Financial Morning Call for Friday, July 31, 2026

Brazil Markets: Ibovespa & the Real — July 31, 2026

Sources: Grupo Profarma.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.